In a series of 108 patients with breast cancer treated with neoadjuvant chemotherapy consisting of a sequential paclitaxel and epirubicin-based schedule, the proportion of ALDH+ CSCs increased significantly, as compared to untreated tumors [36] Lin et al. have recently demonstrated that cisplatin selects for CD133+ lung cancer stem cells by activating notch signaling. Here, PROM1 is linked to breast carcinoma.